The HE4 (Human Epididymal Protein 4) Test is a diagnostic tool primarily used to assess the risk of ovarian cancer in women, especially when evaluating ovarian masses.
HE4 is a protein that can be elevated in cases of ovarian cancer, and the test is often combined with the CA-125 marker to improve diagnostic accuracy. This dual approach helps healthcare providers distinguish between benign and malignant ovarian conditions and monitor treatment response.
1. Early Detection of Ovarian Cancer: The HE4 test aids in identifying ovarian cancer at an early stage, which can lead to better treatment outcomes.
2. Accurate Risk Assessment: When used with CA-125, HE4 provides a clearer picture of ovarian cancer risk, reducing false positives and helping in more accurate treatment planning.
3. Monitoring Disease Progression: For those already diagnosed, the HE4 test is valuable for tracking treatment response and identifying recurrence early on.
Individuals with Ovarian Cancer Symptoms: Women experiencing pelvic pain, bloating, or abnormal bleeding may benefit from this test.
Those with a Family History of Ovarian Cancer: Women with high familial risk can use the HE4 test for routine monitoring.
Patients with Known Ovarian Masses: For women with ovarian masses, the HE4 test can help assess the nature of the mass.
You should choose Diagnopein in Pune for your HE 4 (HUMAN EPIDYMIC PROTEIN) 4 test because we are committed to providing high-quality diagnostic care in a clean and hygienic environment. Our center is equipped with advanced technology to ensure accurate and reliable test results, which are crucial for assessing this test. Diagnopein’s experienced staff is dedicated to handling tests with precision and care, offering you both expertise and comfort. We also offer affordable pricing, making essential health diagnostics accessible without compromising quality. For timely, professional, and affordable cardiac testing, Diagnopein is your trusted partner in Pune.
A blood sample is drawn and analyzed for HE4 protein levels.
Frequency depends on individual risk and healthcare provider recommendations, especially in known ovarian cancer cases.
No, it is typically used alongside CA-125 and other imaging tests to improve diagnostic accuracy.
Not necessarily; some non-cancerous conditions may also elevate HE4, so results must be interpreted with care.
